
| Luncheon Symposium 1 [Amgen] | |||
| 12:20~12:40 |
|
My Clinical Experiences of Evolocumab in Endocrinology 신동엽 (연세의대) |
|
| Luncheon Symposium 1 [Sanofi] | |||
| 12:40~13:00 |
|
Clinical Significance of TIR and the Latest Comparative Study of Second-generation Basal Insulin 김규리 (성균관의대) |
|

| Luncheon Symposium 2 [MSD] | |||
| 12:20-12:40 |
|
How to Find the Optimal Combination Therapy for Patients with Type 2 Diabetes 이승환 (가톨릭의대) |
|
| Luncheon Symposium 2 [Hanmi Pharm] | |||
| 12:40-13:00 |
|
New Lipid Therapy Option for Low & Moderate Risk ASCVD Patients 김상용 (조선의대) |
|

| Luncheon Symposium 3 [Dong-A ST] | |||
| 12:20-12:40 |
|
KDA/ADA 최신 치료지침과 함께 살펴 본 혈당변동성 관리의 중요성 최경묵 (고려의대) |
|
| Luncheon Symposium 3 [JW Pharmaceutical] | |||
| 12:40-13:00 |
|
Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy 이재혁 (한양의대) |
|

| 08:00~08:40 |
|
식후고혈당과 혈당변동성 박철영 (성균관의대) |

| 08:00~08:40 |
|
A Fast-acting Insulin to Improve Glycemic Control 곽수헌 (서울의대) |

| Luncheon Symposium 4 [Yuhan] | |||
| 12:10~12:30 |
|
The Importance of Metabolic-Renal-Cardio Benefit with SGLT2i, Jardiance 양여리 (가톨릭의대) |
|
| Luncheon Symposium 4 [AstraZeneca] | |||
| 12:30~12:50 |
|
Forxiga, a Holistic Approach from Prevention to Treatment of Cardiorenal Benefit in T2D 김수경 (경상의대) |
|

| Luncheon Symposium 5 [Handok] | |||
| 12:10~12:30 |
|
Current Advances and Evidence of Artificial Pancreas System - MINIMEDTM 770G 문선준 (성균관의대) |
|
| Luncheon Symposium 5 [Bukwang Pharmaceutical] | |||
| 12:30~12:50 |
|
Pathogenic Treatment Strategy of Diabetic Peripheral Neuropathy(DPN) 원종철 (인제의대) |
|